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Abstract 
Objectives: The aim of this study was to assess the relationship between serum and  saliva levels of cancer antigen 
(CA) 15-3 and to compare them between women with and  without breast cancer. Study design: A case-control 
study was carried out on 61 women aged 28-69 years,  including women with and without breast cancer (26 as part 
of the case study and 35 as  part of the control group) conducted at the Emam Khomeini Hospital, Tehran University 
of  Medical Sciences. CA15-3 levels were assayed in serum and unstimulated whole saliva by  EIA. Unpaired t-test, 
one-way ANOVA and Pearson correlation were used as statistical  analysis. Results: The salivary and serological 
levels of CA15-3 in the cancer patients were significantly  higher (P <0.01) than the salivary and serum levels of 
healthy controls. They were also  higher in stage 2 than in stage 1 in cancer patients. However, the saliva flow rate 
was  significantly lower in the cancer patients (P <0.01). There was a significant positive  correlation between serum 
and saliva CA15-3 concentration (r = 0.614) and also between  serum concentration and saliva output of CA15-3 
(r = 0.541). Conclusion: The results of the study suggest that salivary CA15-3 may have potential use in the  initial 
detection of breast cancer in women. 
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Introduction
Breast cancer is the most common type of cancer occur-
ring in women. Approximately 1 woman in every 10 will 
develop breast cancer in her lifetime (1). Therapy for 
advanced breast cancer has not improved significantly in 
recent years, remaining strictly palliative in nature and 
intent (2). The diagnosis of breast cancer at an earlier 
stage allows a woman more choice in the selection of 
treatment option (3).
 While physical examination and mammography are use-
ful screening procedures for the early detection of breast 
cancer, they are also labor intensive and require health 
professionals who are highly trained and experienced. 
Also, despite efforts to provide accurate diagnosis, these 
screening procedures can produce a substantial percent-
age of false positive and false negative results, especially 
in woman with dense parenchymal breast tissue (1).
Tumor markers are substances identified in the circula-
 doi:10.4317/medoral.14.e521
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tion of patients with malignant disease, which may be 
used in diagnosis (early detection and differential diag-
nosis), prognostic evaluation and follow–up (therapeutic 
monitoring and diagnosis of recurrence) (4).   
CA 15-3 is a mucinous glycoprotein that has been de-
tected in elevated amounts in serum of women with 
breast cancer. Longitudinal studies of healthy woman 
have demonstrated the statistical significance of this 
marker to monitor breast cancer patients (3). 
Several studies show that cancer markers often detect 
metastasis before a clinical manifestation (5,6). It has 
been determined that a number of tumor markers are 
present in saliva therefore its use as a diagnostic fluid 
could have significant diagnostic and logistical advan-
tages when compared to serum (1). As diagnostic medi-
um, saliva has several advantages , including collection 
of saliva is safe , non invasive , and simple , and it may 
be collected repeatedly without discomfort to the patient, 
and could also be a cost-effective means to monitor the 
effectiveness of chemotherapy (1,7).
The aim of this study is to assess the relationship bet-
ween serum and saliva levels of cancer antigen (CA) 
15-3 and compare them between women with and wit-
hout breast cancer. 
Materials and Methods
- Subjects:
Sixty one women participated in a case–control study, 
conducted at the Emam Khomeini Hospital, Tehran Uni-
versity of Medical Sciences from summer 2007 to sum-
mer 2008. Case group (n=26) included women with un-
treated breast carcinoma (mean age 42.6, ranging from 
31 to 63 years) who were candidate for surgery of breast 
cancer. An oncologist and physician approved the breast 
tumor and its stage after biopsy. None of case group 
was metastatic breast cancer. Control group included 35 
healthy women (average age 43.6 ranging in age from 
28 to 69 years). Majority of participants in control group 
were relative of patients in case group. Health status 
was determined by questionnaire, and each participant 
received a through physical examination and was eval-
uated for carcinoma of the breast by a physician. The 
groups were matched in age, menopausal status, dura-
tion of menopause and contraceptive usage.
All participants were administered a brief questionnaire 
at the time of signing consent form. These data were col-
lected by interview and included information concern-
ing age, tobacco usage, and pharmacological and medi-
cal histories (Table 1).        
The Ethics Committee of TUMS, Iran, approved the 
study protocol. Informed consent was obtained from all 
participants.
- Sample collection:
Venous blood and unstimulated whole saliva were col-
lected simultaneously from each participant in the 
morning. Unstimulated whole saliva was collected by 
the spitting method. All subjects refrained from eating, 
drinking and smoking for 2 hours prior to the sampling. 
Each individual rinsed her mouth thoroughly with water, 
was seated for approximately 5 minutes, before 5 ml of 
unstimulated saliva was collected into a plastic cup over 
a period of about 15 minutes.
Blood specimens were obtained by venipuncture, col-
lected in 10 ml glass vacuum tubes without additive, and 
allowed to clot. Then blood and saliva were centrifuged 
(2000 rpm, 10 min) and the serum and supernatants of 
saliva were separated. Immediately after collection of 
saliva and serum, the specimens were stored at -70 °C 
for later determination of cancer antigens CA15-3.
The saliva-filled cups were weighed and the weight of 
the cups subtracted. The flow rate was calculated in g/
min, which is almost equivalent to ml/min (8). Saliva 
CA15-3 output was calculated as saliva CA15-3 concen-
tration multiply saliva flow rate.
- CA15–3 assays:
CA15-3 tests were performed by using a two-site solid 
phase enzyme immunoassay (EIA) kits (CanAg Diag-
nostics AB; Gothenburg, Sweden). The molecules of 
CA15–3 are “sandwiched” between two monoclonal 
antibodies. The first one is attached to the ELISA so-
lid phase and the second one linked to the horseradish 
peroxidase (enzymatic conjugate). After washing, the 
enzymatic reaction develops a color proportional to the 
amount of CA15–3 present in the assay. Absorbance is 
read at 405 nm (horseradish peroxidase) using a spectro-
photometer and the concentration are calculated from a 
standard curve constructed from known concentrations 
of the ligand. The CA15-3 EIA kit is designed to assay 
serum specimens. 
- Statistical analysis:
Statistical analyses were performed using the SPSS sta-
tistical software package. The data are presented as a 
mean ± SEM. Comparisons between the case and con-
trol groups were made with the unpaired t-test. One-way 
ANOVA (analysis of variance) followed by Student-
Healthy 
women
Women with 
breast cancer
n 35 26
Age (years, mean (range)) 43.6(28 - 69) 42.6 (31 - 63)
Tobacco usage (n) 0 0
Menopause (n) 16 13
Duration of menopause 
(range years) 1-13 1-12
Contraceptive usage (n) 9 6
Table 1. Demographic data obtained from the questionnaires for 
the two groups of women.
e523
Med Oral Patol Oral Cir Bucal. 2009 Oct 1;14 (10):e521-4.                                                                                                                                              Serum and saliva CA15-3 in breast cancer
Newman-Keuls post-hoc test was performed when com-
parisons between the three groups were made. The Pear-
son correlation analysis was used to identify any corre-
lation between serum and the salivary CA15-3 compo-
nents. P < 0.05 was considered statistically significant.
Results 
The mean unstimulated whole saliva flow rate, saliva 
CA15-3 concentration and its output and serum CA15-3 
concentration are shown in Table 2. Student’s t- test 
showed that unstimulated whole salivary flow rate was 
significantly higher in control group than case group 
(P<0.01), but serum CA15-3 concentration (P<0.001), 
saliva CA15-3 concentration (P<0.001) and salivary 
CA15-3 output (P<0.01) were significantly higher in 
case group.
A one-way ANOVA indicated that saliva flow rate [F2,58= 
3.2; P<0.05], serum CA15-3 concentration [F2,58= 88.3; 
P<0.001], salivary CA15-3 concentration [F2,58= 23.5; 
P<0.001] and its output [F2,58= 5.9; P<0.01] were sig-
nificantly differ between healthy women, women with 
breast cancer in stage 1 and in stage 2 (Table 2). Post-
hoc analysis showed that saliva and serum CA15-3 
concentrations were significantly higher in both women 
with breast cancer in stage 1 and 2 than healthy individu-
als and also higher in stage 2 than stage 1. Saliva flow 
rate and salivary CA15-3 output were not significant be-
tween stages of 1 and 2.
The correlations coefficients revealed a significant mod-
erate association between serum and salivary CA15-3 
concentration at r = 0.614 (P < 0.001; Fig. 1a). There was 
also a significant association between serum CA15-3 
concentration and salivary CA15-3 output (r = 0.541, P 
= 0.001; Fig. 1b).
Healthy women 
(n=35)
Women with 
breast cancer 
(n= 26)
Women with 
breast cancer,
Stage 1 (n=15)
Women with 
breast cancer, 
Stage 2 (n= 11)
Saliva flow rate (ml/min) 0.55±0.06 0.33±0.04 * 0.34±0.06 0.32±0.05 *
Serum CA15-3 (ng/ml) 8.68±0.51 18.56±1.94 * 12.49±1.27 * 28.67±1.91 *#
Saliva CA15-3 (ng/ml) 1.02±0.09 2.92±0.45 * 2.17±0.35 * 4.24±0.96 *#
Saliva CA15-3 output (ng/min) 0.55±0.07 0.94±0.15 * 0.77±0.13 1.27±0.36 *
?
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Table 2. Mean and SE values for saliva flow rate and salivary and serum CA 15-3.
 * P<0.05 vs healthy women and # P<0.05 vs women with breast cancer in stage 1
Fig.1. Relationship between serum and unstimulated whole saliva CA15-3 concentrations (a), and between serum CA15-3 
concentration and saliva CA15-3 output (b) in women as determined by Pearson correlation coefficient, * P< 0.05.
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Discussion 
Saliva as a diagnostic specimen can give not only the 
same information as serum testing, but also additional or 
new information that cannot be obtained from serum (9). 
From a logistical perspective, the collection of saliva is 
safe, noninvasive, and simple, and it may be collected 
repeatedly without discomfort to the patient. Because 
of these significant characteristics, finding biomarkers 
in saliva for the detection of serious systemic illnesses, 
such as cancer, is of great interest for most salivary re-
searchers (7,10) ). CA15-3, a high-molecular-mass mu-
cin-like glycoprotein, is expressed at the luminal surface 
of most secretary epithelial (11). Of the tumor markers 
examined in breast cancer, it is the best and the most 
extensively used one as its expression greatly increases 
in most breast carcinomas (12). It was also shown that 
levels of circulating CA15-3 correlated with tumor size, 
thus reflecting disease stage (13,14). Our data showed 
that saliva and serum levels of CA15-3 were significant-
ly correlated with tumor stage. It is in agreement with 
other studies. 
Our results also indicated that the mean serum CA15-3 
was significantly higher in untreated breast cancer group 
than in healthy women. It is in agreement with other re-
ports (4,12,15-19). 
Our results also illustrated that the mean unstimulated 
whole saliva CA15-3 concentration and its output were 
significantly higher in breast cancer group than control 
women. These results confirm with the results of other 
reports about stimulated whole saliva CA15-3 levels in 
breast cancer (17,18). To our knowledge there was no 
report about the unstimulated whole saliva CA15-3 in 
breast cancer. 
The serum concentration of CA15-3 revealed signifi-
cant correlation with unstimulated whole saliva CA15-3 
concentration and output. Results suggest that salivary 
CA15-3 may have a role in monitoring and in manage-
ment of breast cancer.
The results of this study demonstrated that the unstimu-
lated salivary flow rate of the healthy women was sig-
nificantly higher than breast cancer group. As salivary 
flow rate decreased in stress, saliva flow rate decreasing 
may be due to the stress of cancer in women with breast 
cancer.
In conclusion, the results of this study show that there 
are positive correlations in CA15-3 between serum and 
unstimulated whole saliva levels, and salivary out put. It 
seems that salivary CA15-3 may have a role in monitor-
ing and in management of breast cancer.
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